Scholar Rock Unveils Remarkable SRK-439 Findings: Preserving Lean Mass, Curbing Fat Gain
Scholar Rock, a biotechnology company, has initiated the Phase 2 EMBRAZE trial to evaluate apitegromab, a myostatin inhibitor, for...
A Remarkable New Path: Unlocking Precision Nutrition
Institute for Systems Biology (ISB) researchers have developed a new method to predict individual-specific short-chain fatty acid (SCFA) production...
Surprising Insights on Clinical Trial Digital Transformation
According to a recent report, “The State Of Digital Excellence In The Global Pharmaceutical Industry, 2023: Clinical Operations,” by...
Tectonic Merger Delivers Hope for Gene Therapy Breakthroughs
Tectonic Therapeutic, Inc. (TECX) has merged with AVROBIO, Inc. and will operate as Tectonic Therapeutic, Inc., trading on Nasdaq...
Groundbreaking Treatment: Elevidys Expands Access for Duchenne Patients
The U.S. Food and Drug Administration (FDA) has granted traditional approval to ELEVIDYS for ambulatory Duchenne muscular dystrophyDuchenne muscular...
Lenacapavir: Revolutionary Injection Beats Truvada for HIV Prevention
A phase 3 clinical trial known as PURPOSE 1 has yielded breakthrough results in HIV prevention. The trial studied...
Unveiling the Remarkable Team Driving a Revolutionary Pediatric Cancer Vaccine
CellxLife, a newly established company, aims to revolutionize treatment for children with recurring metastatic Ewing sarcoma and osteosarcoma. The...
Precision Biosciences Enhances Hepatitis Scientific Advisory Board with Renowned Investigators
Precision BioSciences, a gene editing company, has appointed Dr. Mark Sulkowski and Dr. Jordan Feld to its Hepatitis Scientific...
EMA Validates Bristol Myers Squibb’s Subcutaneous Nivolumab Filing
Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has accepted an extension application for a new...
Bristol Myers Squibb Introduces FDA-Approved Krazati® for Metastatic Colorectal Cancer
The FDA has approved KRAZATI (adagrasib) in combination with cetuximab as a treatment for locally advanced or metastatic colorectal...